Beth-Israel Deaconess Medical Center
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elranatamab in R/R Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-08-31 | NCT06138275 | |
| The Young Women's Breast Cancer Study | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-02-03 | NCT01468246 | |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | B-cell neoplasm, Digestive System Diseases, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, aggressive B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, digestive system disorder, hypertrophic pyloric stenosis, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, pyloric stenosis, stomach disorder | Active, not recruiting | Phase 2 | 2026-01-29 | NCT05583149 | |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, thrombocytosis disease | Recruiting | Phase 2 | 2026-01-08 | NCT04644211 | |
| Folfox+Irinotecan+Chemort In Esophageal Cancer | gastroesophageal junction adenocarcinoma | Recruiting | Phase 2 | 2025-11-14 | NCT04656041 |